In April 2018, Tango Biosciences received a R41 award from NIH. The goals of the grant are to generate two-site capable affinity reagents through MegaSTAR to two sets of targets. One set represents biomarkers of colorectal cancer and myocardial infarction. MegaSTAR reagents will be benchmarked against existing commercial sandwich reagents, and the performance metrics (i.e., intra-assay and inter-assay precision, linearity, sensitivity) will be evaluated and compared through ELISA. The second set of targets is a family of membrane proteins. Successful production of specific affinity reagents to the ectodomains will showcase the potential of MegaSTAR to generate reagents to challenging targets.
NIH STTR award
More News and Events
-
Event
SLAS 2025
Visit Tango Biosciences at the 2025 SLAS International Conference & Exhibition! January 25-29, 2025 | San Diego, CA Booth #2317 Plus, mark your calendar to join our Solution Spotlight presentation: Rapid Phage Display Solutions ideal for SLAS: Screening Ligands for Affinity and Selectivity Tuesday, January 28 | 5:00 PM – 5:20 PM PST
-
News
NIH SBIR Award
The National Institutes of Health (NIH) awarded a phase I grant to Tango Biosciences in January 2021. This award will support a collaborative effort that generates recombinant antibodies and antibody-like reagents for 6 SARS-CoV-2 viral proteins. These reagents will aid scientists in understanding the function of these viral proteins inside infected cells. Such information may […]
-
News
Tango Biosciences publishes work on SARS-CoV-2 virus
Tango Biosciences scientists, in collaboration with colleagues from B2S Life Sciences, LifeTein, and Euprotein, publish a scientific report on generating recombinant affinity reagents (monobodies) to the receptor binding domain (RBD) of the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. Soluble forms of the monobodies bound to several different preparations of the RBD and […]